Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

B2M mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

B2M mutation	Mantle Cell Lymphoma	B2M mutation	Mantle Cell Lymphoma	acalabrutinib Resistant: C3 – Early Trials acalabrutinib Resistant : C3	acalabrutinib Resistant: C3 – Early Trials acalabrutinib Resistant : C3
B2M mutation	Hodgkin Lymphoma	B2M mutation	Hodgkin Lymphoma	sintilimab Resistant: C3 – Early Trials sintilimab Resistant : C3	sintilimab Resistant: C3 – Early Trials sintilimab Resistant : C3
B2M mutation	Diffuse Large B Cell Lymphoma	B2M mutation	Diffuse Large B Cell Lymphoma	rituximab Resistant: C3 – Early Trials rituximab Resistant : C3	rituximab Resistant: C3 – Early Trials rituximab Resistant : C3
B2M mutation	Melanoma	B2M mutation	Melanoma	pembrolizumab Resistant: C4 – Case Studies pembrolizumab Resistant : C4	pembrolizumab Resistant: C4 – Case Studies pembrolizumab Resistant : C4